To the best of our knowledge, this meta-analysis includes the largest sample size analyzed to date and determined the role of EGFR-TKIs in an adjuvant setting in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.